دورية أكاديمية
أعرض في EDS

In Situ - Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation.

التفاصيل البيبلوغرافية
العنوان: In Situ - Forming Microparticles for Controlled Release of Rivastigmine: In Vitro Optimization and In Vivo Evaluation.
المؤلفون: Haider M; Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, UAE.; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, UAE.; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 71526, Egypt., Elsayed I; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 71526, Egypt.; Department of Pharmaceutical Sciences, College of Pharmacy, Gulf Medical University, Ajman 04184, UAE., Ahmed IS; Department of Pharmaceutics and Pharmaceutical Technology, College of Pharmacy, University of Sharjah, Sharjah 27272, UAE.; Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah 27272, UAE., Fares AR; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 71526, Egypt.
المصدر: Pharmaceuticals (Basel, Switzerland) [Pharmaceuticals (Basel)] 2021 Jan 14; Vol. 14 (1). Date of Electronic Publication: 2021 Jan 14.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101238453 Publication Model: Electronic Cited Medium: Print ISSN: 1424-8247 (Print) Linking ISSN: 14248247 NLM ISO Abbreviation: Pharmaceuticals (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, c2004-
مستخلص: In this work, sucrose acetate isobutyrate (SAIB) and polylactic co-glycolic acid (PLGA) were used alone or in combination as a matrix-former (MF) to prepare long-acting injectable rivastigmine (RV) in situ - forming microparticles (ISM). RV-ISM were prepared by the emulsification of an internal phase, containing the drug and the matrix former(s), into an external oily phase containing a stabilizer. The statistical design, Central Composite Design (CCD), was adopted as a quality by design (QbD) approach to optimize the formulation of RV-ISM systems. The fabricated RV-ISM systems was designed to minimize the initial burst drug release and maximize the sustainment of RV release from the ISM and ease of injection. The influence of critical formulation variables such as the matrix-former to drug (MF/D) ratio and SAIB to PLGA (S/P) ratio in the internal phase with respect to critical quality attributes (CQAs), such as the percentage drug release within the first day (Q 1 ), the time required for 50% drug release (T 50% ) and the rate of injection, were studied using the CCD. The optimal RV-ISM system with the highest desirability value (0.74) was predicted to have an MF/D ratio of 11.7:1 ( w / w ) and an S/P ratio of 1.64:1 ( w / w ). The optimal RV-ISM system was assessed for its release profile, injectability, rheological properties, morphology, effect on cell viability, tolerance to γ-sterilization and in vivo performance in male albino rabbits. In vitro release studies revealed that the optimal RV-ISM system released 100% of its drug content throughout a release period of 30 days with only 15.5% drug release within the first day (Q 1 ) and T 50% of 13.09 days. Moreover, the optimal system showed a high injection rate of 1.012 mL/min, pseudoplastic flow, uniform spherical globules with homogenous particle size, minimal cytotoxicity and high tolerability to γ-sterilization. In vivo pharmacokinetic (PK) studies revealed that the rate of absorption of RV from the optimal RV-ISM system was controlled compared to a drug solution following either intramuscular (IM) or subcutaneous (SC) injection. Furthermore, the optimal RV-ISM was found to follow flip-flop PK with poor correlation between in vitro release and in vivo findings. These findings suggest that the optimal RV-ISM is a promising tool to achieve a sustained release therapy for RV; however, further investigation is still required to optimize the in vivo performance of RV-ISM.
References: Med Biol Eng Comput. 1999 Sep;37(5):645-51. (PMID: 10723904)
AAPS PharmSciTech. 2018 Apr;19(3):1001-1010. (PMID: 29110291)
J Control Release. 2012 Jul 20;161(2):505-22. (PMID: 22353619)
Vaccine. 2000 Oct 15;19(4-5):492-7. (PMID: 11027813)
J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1056-63. (PMID: 17353259)
Clin Pharmacokinet. 2013 Apr;52(4):225-41. (PMID: 23408070)
Clin Pharmacol Ther. 2008 Jan;83(1):106-14. (PMID: 17522596)
J Control Release. 2002 Apr 23;80(1-3):9-28. (PMID: 11943384)
J Microencapsul. 2000 May-Jun;17(3):343-62. (PMID: 10819422)
Clin Interv Aging. 2007;2(1):17-32. (PMID: 18044073)
J Control Release. 2005 Nov 28;108(2-3):282-93. (PMID: 16229919)
Int J Pharm. 2001 Jun 4;220(1-2):77-83. (PMID: 11376969)
J Control Release. 2019 Jun 28;304:125-134. (PMID: 31071374)
Ther Deliv. 2011 May;2(5):643-72. (PMID: 21837267)
Acta Pharm. 2008 Sep;58(3):287-97. (PMID: 19103565)
Eur J Pharm Sci. 2008 Jul 3;34(2-3):164-72. (PMID: 18501569)
J Mater Sci Mater Med. 2012 Feb;23(2):443-55. (PMID: 22170300)
Int J Pharm. 2007 Mar 6;332(1-2):107-14. (PMID: 17084049)
Pharm Res. 2015 Nov;32(11):3708-21. (PMID: 26077999)
Bone. 1999 Aug;25(2 Suppl):31S-34S. (PMID: 10458271)
AAPS PharmSciTech. 2007 Aug 03;8(3):E62. (PMID: 17915812)
Food Chem Toxicol. 1998 Feb;36(2):95-9. (PMID: 9519847)
Drug Dev Ind Pharm. 1999 Feb;25(2):247-51. (PMID: 10065360)
Int J Clin Pract. 2009 May;63(5):799-805. (PMID: 19392927)
J Pharm Sci. 2019 Jun;108(6):2112-2118. (PMID: 30685397)
Food Cosmet Toxicol. 1976 Oct;14(5):375-80. (PMID: 1010504)
Curr Drug Deliv. 2005 Jan;2(1):35-44. (PMID: 16305406)
J Pharm Sci. 2007 Dec;96(12):3252-62. (PMID: 17721936)
J Basic Clin Pharm. 2016 Mar;7(2):27-31. (PMID: 27057123)
J Pharm Pharmacol. 2012 Oct;64(10):1425-37. (PMID: 22943173)
Pharmaceutics. 2020 Aug 30;12(9):. (PMID: 32872639)
FASEB J. 2008 Mar;22(3):659-61. (PMID: 17942826)
Alzheimer Dis Assoc Disord. 2002 Oct-Dec;16(4):203-12. (PMID: 12468894)
Mater Sci Eng C Mater Biol Appl. 2018 Nov 1;92:1041-1060. (PMID: 30184728)
J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):292-4. (PMID: 14742608)
Eur J Immunol. 1975 Apr;5(4):270-4. (PMID: 1086232)
Curr Drug Deliv. 2019;16(4):331-340. (PMID: 30451111)
Drug Deliv. 2015;22(7):918-30. (PMID: 24467601)
Macromol Biosci. 2008 Mar 10;8(3):247-59. (PMID: 18041108)
Int J Pharm. 2001 Jan 5;212(1):11-8. (PMID: 11165816)
Eur J Pharm Biopharm. 2004 Sep;58(2):445-55. (PMID: 15296966)
J Clin Pharmacol. 2005 Nov;45(11):1259-67. (PMID: 16239359)
Eur J Pharm Sci. 2009 Mar 2;36(4-5):524-31. (PMID: 19124076)
Drug Deliv. 2019 Dec;26(1):532-541. (PMID: 31090468)
Drug Dev Ind Pharm. 2013 Mar;39(3):466-80. (PMID: 22409834)
Drug Dev Ind Pharm. 2012 Aug;38(8):971-8. (PMID: 22092113)
Pharm Res. 2008 Apr;25(4):845-52. (PMID: 17694395)
Pharm Res. 2000 Oct;17(10):1323-8. (PMID: 11145241)
Curr Drug Deliv. 2018;15(8):1193-1203. (PMID: 29557743)
Macromol Biosci. 2006 Dec 8;6(12):977-90. (PMID: 17128422)
Biomaterials. 2002 Nov;23(22):4353-8. (PMID: 12219825)
Int J Pharm. 2012 Sep 15;434(1-2):251-6. (PMID: 22677417)
J Control Release. 2012 Jul 20;161(2):668-79. (PMID: 22543012)
J Pharm Sci. 1963 Dec;52:1145-9. (PMID: 14088963)
معلومات مُعتمدة: V.C./G.R.C./S.R. 316/2015 University of Sharjah; AJF201777 Aljalila foundation
فهرسة مساهمة: Keywords: depot release; in situ-forming microparticles; optimization; rivastigmine; sucrose acetate isobutyrate
تواريخ الأحداث: Date Created: 20210120 Latest Revision: 20210218
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC7829814
DOI: 10.3390/ph14010066
PMID: 33466880
قاعدة البيانات: MEDLINE
الوصف
تدمد:1424-8247
DOI:10.3390/ph14010066